

This item is the archived peer-reviewed author-version of:

Vitamin B-12 deficiency in the setting of nitrous oxide abuse: diagnostic challenges and treatment options in patients presenting with subacute neurological complications

Reference:

Yasmine Sluyts, Pieterneel Vanherpe, Rizvana Amir, Vanhoenacker Filip, Vermeersch Pieter.- Vitamin B-12 deficiency in the setting of nitrous oxide abuse: diagnostic challenges and treatment options in patients presenting with subacute neurological complications
Acta clinica Belgica / Belgian Society of Internal Medicine [Ghent]; Royal Belgian Society of Laboratory Medicine - ISSN 1784-3286 - (2021), p. 1-7
Full text (Publisher's DOI): <https://doi.org/10.1080/17843286.2021.2015555>
To cite this reference: <https://hdl.handle.net/10067/1847950151162165141>

1 ~~Neurological complications due to v~~Vitamin B₁₂ deficiency in the setting of nitrous
2 oxide abuse: diagnostic challenges and treatment options in patients presenting with
3 subacute neurological complications.

4 Sluys Yasmine^{a,b}, MD; Vanherpe Pieterne^a, MD; Amir Rizvana^a, MD; Pals Philippe^{a,c},
5 MD, PhD; Vanhoenacker Filip^d, MD, PhD; and Vermeersch Pieter^e, MD, PhD

6
7 ^aDepartment of Neurology, Antwerp University Hospital (UZA), Drie Eikenstraat 655, 2650
8 Edegem, Belgium

9 ^bFaculty of medicine and health sciences, University of Antwerp (UA), Universiteitsplein 1,
10 2610 Wilrijk, Belgium

11 ^cDepartment of Neurology, AZ Sint-Maarten, Liersesteenweg 435, 2800 Mechelen, Belgium.

12 ^dDepartment of Radiology, AZ Sint-Maarten, Liersesteenweg 435, 2800 Mechelen, Belgium and
13 Faculty of medicine and health sciences, University of Antwerp (UA) and Faculty of medicine
14 and health sciences, University Ghent.

15 ^eDepartment of Laboratory Medicine, University Hospitals Leuven, Herestraat 49, 3000
16 Leuven, Belgium

17
18 **Keywords**

19 Nitrous oxide, vitamin B₁₂ deficiency, neurological symptoms, diagnosis, treatment.

20
21 * Correspondence to: Pieterne Vanherpe

22
23 Abstract: 164 words

24 Article: words

25

1 Abbreviations: crea: creatinine, tHCy: homocysteine, MCA: 2-methylcitric acid, MMA:
2 methylmalonic acid; MRI: magnetic resonance imaging; SEP:
3 Somatosensory evoked potentials

5 **Declaration of interest**

6 Funding: this work received no fundings.

7 Disclosure statement: no conflicts of interest.

9 Acknowledgement

10 Professor P. Vermeersch is a senior clinical investigator of the FWO Vlaanderen.

Met opmaak: Lettertype: (Standaard) Times New Roman, 12 pt

Met opmaak: Lettertype: Vet

1 **Abstract**

2 It is well recognized that nitrous oxide abuse can lead to vitamin B₁₂ deficiency presenting
3 with neurological complications. Nevertheless, establishing this diagnosis can be
4 challenging and treatment guidelines are lacking. In this paper we present a case series of
5 eight patients and discuss the diagnostic challenges and treatment options for vitamin B₁₂
6 deficiency due to nitrous oxide abuse presenting with neurologic complications.
7 Biochemical findings are not always straightforward and complementary testing is often
8 necessary. Magnetic Resonance Imaging (MRI) revealed a longitudinally myelopathy
9 extending over a long segment typically involving the dorsal columns of the cervical cord.
10 To increase the lesion conspicuity, dedicated MRI sequences are needed. In our practice,
11 we recommend the use of T2-weighted images [\(WI\)](#) with fat suppression [\(FS\)](#). Treatment
12 consists of cessation of nitrous oxide abuse and supplementation with intramuscular
13 injections of cobalamin. Because of a lack of treatment guidelines, we also describe the
14 treatment schedule used in our neurology clinic and give a brief overview of treatment
15 options suggested in the literature.

1 **Introduction**

2 The traditional clinical findings associated with severe vitamin B₁₂ deficiency are
3 macrocytic anemia and variable neuropsychiatric symptoms. The clinical presentation is,
4 however, often more subtle and many cases are only identified in response to incidental
5 hematological findings. Causes of vitamin B₁₂ deficiency include dietary deficiency (e.g.,
6 strict vegan diet), pernicious anemia, decreased gastrointestinal absorption (e.g., celiac
7 disease, gastric atrophy), certain drugs (e.g., metformin) and nitrous oxide abuse.

8 In patients with classical megaloblastic anemia, ~~the presence of a~~ low serum cobalamin
9 level and ~~objective assessment of response in terms of the a~~ rise in hemoglobin
10 ~~concentration after supplementation~~ clearly outlines the treatment pathway. However,
11 most patients do not have such a clear-cut picture. In this case establishing the diagnosis
12 of a vitamin B₁₂ deficiency can be challenging. A serum vitamin B₁₂ below 200 ng/L is
13 typically considered low and consistent with a deficiency (1). While more than 95% of
14 patients with megaloblastic anemia have a serum vitamin B₁₂ below 200 ng/L (1), the
15 sensitivity in patients without overt symptoms is significantly lower (2). This is
16 particularly true for vitamin B₁₂ deficiency due to nitrous oxide (3). Vice versa, the
17 significance of low cobalamin levels in patients with non-specific symptoms and without
18 anemia is also uncertain. To improve the specificity and sensitivity, additional testing is
19 often recommended when serum vitamin B₁₂ is below 200 ng/L or between 200 ng/L and
20 300 ng/L. Homocysteine (HCy) is typically elevated both in vitamin B₁₂ and folic acid
21 deficiency, while methylmalonic acid (MMA) is only elevated in vitamin B₁₂ deficiency.
22 Of note, MMA in plasma is not widely available due to the relatively high cost (1, 3).
23 While measuring HCy and MMA can help in the diagnosis of vitamin B₁₂ deficiency, the
24 results of HCy and MMA can also be inconclusive (1).

1 The most common neurological complications due to vitamin B₁₂ deficiency in the setting
2 of nitrous oxide abuse or ‘laughing gas’ are numbness, paresthesia, weakness, and gait
3 difficulties (4, 5). These symptoms are caused by subacute combined degeneration and
4 sensorimotor polyneuropathy (3, 4). In clinical practice, we regularly encounter patients
5 with neurologic complications due to functional vitamin B₁₂ deficiency caused by nitrous
6 oxide abuse. Given the fact patients are often reluctant to admit nitrous oxide abuse, the
7 diagnosis is often challenging.

8 In this paper we present clinical, biochemical, and radiological data of eight patients and
9 discuss the ~~diagnostic challenges~~diagnostic testing strategy and treatment options of
10 vitamin B₁₂ deficiency in the setting of nitrous oxide abuse. All eight cases were
11 diagnosed within fifteen months of the start of the COVID-19 pandemic. Six of our eight
12 patients ultimately admitted to recreational use of nitrous oxide. Two of our patients
13 denied personal use of nitrous oxide, but may have been affected due to passive exposure
14 to nitrous oxide as bystanders based on the patient interview (6)–(7). Other causes of
15 vitamin B12 deficiency were excluded. None of the patients followed a strict vegan diet,
16 had pernicious anemia, took a proton pump inhibitor or had celiac disease.

17

18 **Case 1**

19 A 19-year-old male presented with subacute gait difficulties, ~~originated over~~since one
20 week. He reported progressive weakness and sensory disturbances in the lower limbs. He
21 admitted to abusing nitrous oxide frequently for over two years. Physical examination
22 revealed an ataxic gait with ~~normal~~normal reflexes. There was a T6 sensory level
23 with absent sense of vibration in both legs. Romberg’s sign was negative.

24 The patient’s blood work revealed a normal full blood count and normal vitamin B₁₂ of
25 220 ng/L [reference range: 187 – 883ng/L], with an elevated HCy level of 59.5 μmol/l

1 [7.0 – 15.0 μmol/L]. MMA levels and 2-methylcitric acid (MCA) levels in morning urine
2 were elevated, respectively 427 mmol/mol creatinine [≤ 1 mmol/mol crea] and 21
3 mmol/mol crea [≤ 2 mmol/mol crea]. There were no abnormalities in cerebrospinal fluid
4 (CSF) testing. EMG was not performed, but tibialis SEP (somatosensory evoked
5 potentials) was abnormal. MRI of the cervical spinal cord showed an inverted V-sign on
6 axial FS T2-WI.

7 He was treated with intramuscular hydroxocobalamin. He regained a normal gait.
8

9 **Case 2**

10 An 18-year-old male was evaluated in our neurology clinic because of subacute
11 paresthesia in fingers and lower limbs, as well as walking difficulties and balance
12 problems. The cComplaints progressed over three weeks. On physical examination
13 tendon reflexes were weak and ankle reflexes were absent. Superficial as well as deep
14 sensory testing was reduced, and there was an ataxic gait. Romberg's sign was negative.

15 He admitted to abusing nitrous oxide frequently.

16 Blood examination revealed a normal level of vitamin B₁₂ of 482 ng/L and an elevated
17 level of HCy of 39 mmol/L. CSF protein level was slightly increased (47 mg/dL, [15-
18 40mg/dL]) with a normal cytos. Electromyography (EMG) showed a pattern of axonal
19 ~~more~~rather than demyelinating neuropathy in the lower limbs. Tibialis SEP was
20 abnormal. MRI of the cervical spine showed an inverted V-sign on axial FS T2-WI. MMA

21 and MCA in morning urine after the start of intramuscular supplementation were normal.
22 He was treated with intramuscular cyanocobalamin and physiotherapy. He regained a
23 normal gait.
24

25 **Case 3**

1 A 30-year-old male presented to the emergency department with subacute progressive
2 sensory disturbances and subjective weakness in both upper and lower limbs. progressed
3 over one week. Nitrous oxide abuse was denied. He did admit to attending parties where
4 nitrous oxide was inhaled. On examination, there was a hyporeflexia in upper and
5 areflexia in lower limbs. Superficial as well as deep sensory testing were affected. His
6 gait was normal ~~and Romberg's sign negative~~. Romberg's sign was negative.
7 Blood testing revealed a reduced vitamin B₁₂ level of 180 ng/L and an elevated HCy level
8 of 44.6 μmol/L. Morning urine MMA as well as MCA levels were elevated (both 9
9 mmol/mol crea). CSF showed a minimal elevated protein level of 45 mg/dL with a normal
10 cytosin.
11 EMG showed a mild axonal neuropathy. Tibialis SEP was not performed. Magnetic
12 Resonance Imaging (MRI) revealed bilateral increased T2-signal intensity in the dorsal
13 columns C3 through C5, with an inverted V-sign on axial FS T2-WI weighted images
14 (WI) with fat suppression (FS) (figure 1). There was no enhancement after administration
15 of gadolinium-based contrast agent.

16 The patient was treated with intramuscular cyanocobalamin. He was lost to follow-up.

17

18 **Case 4**

19 A 19-year-old woman presented with a one-week history of progressive numbness and
20 paresthesia in upper and lower limbs. She said she did not use nitrous oxide herself, but
21 did attend gatherings where nitrous oxide was used. Physical examination revealed an
22 ataxic gait with absent deep tendon reflexes. Superficial as well as deep sensory testing
23 were affected. Romberg's sign was positive.

24 The patient's blood work showed a normal B₁₂ level of 330 ng/L, with an elevated HCy
25 level of 25.9 μmol/L. MMA and MCA were elevated in morning urine (31 mmol/mol

1 crea and 5 mmol/mol crea, respectively). Further testing was negative. There were no
2 abnormalities in CSF testing. EMG showed a mild axonal neuropathy. Tibialis SEP was
3 not performed. MRI of the cervical spine revealed a hyperintense signal of the dorsal
4 columns extending from C2 to C6 with an inverted V-sign on axial FS T2-WI (figures
5 2A and C). There was no enhancement after administration of gadolinium-based contrast
6 agent.

7 The patient was treated with intramuscular cyanocobalamin and physiotherapy, with slow
8 recovery of gait.

9

10 **Case 5**

11 An 18-year-old woman presented with subacute numbness and paresthesia in the lower
12 limbs which extended to the upper limbs. Complaints progressed over six weeks. She
13 admitted abusing large amounts of nitrous oxide during several months. Physical
14 examination revealed an ataxic gait with weak deep tendon reflexes in upper and lower
15 limbs. Sensory testing was affected in more in the lower more than in upper limbs.

16 Laboratory workup showed a normal vitamin B₁₂ of 280 ng/L with an elevated HCy of
17 32.4 μmol/L. MMA in morning urine was elevated (10 mmol/mol crea). Tibialis SEP was
18 abnormal. EMG showed a pronounced axonal sensorimotor polyneuropathy and an
19 inverted V-sign on axial FS T2-WI was seen.

20 She was treated with intramuscular cyanocobalamin. An improvement of her gait was
21 observed over weeks.

22

23 **Case 6**

1 A 22-year-old male presented because of progressive numbness in upper and lower limbs
2 for three months. He admitted to infrequent abuse of nitrous oxide. Neurological
3 examination was normal-

4 Examination of his blood showed a normal vitamin B₁₂ of 280 ng/L with an elevated HCy
5 of 48.5 μmol/L. -MMA and MCA were both elevated (4 and 3 mmol/mol creatinine,
6 respectively). EMG nor tibialis SEP were performed. MRI of the cervical spine revealed
7 a doubtful inverted V-sign on the axial FS T2-WI because of artefacts.

8 He was treated with intramuscular cyanocobalamin. On-and-lost-to follow-up, sensory
9 complaints had dissapeared afterwards.

10

11 *Case 7*

12 A 24-year-old male consulted because of subacute progressive sensibility disorders-loss
13 in upper and lower limbs since a few over days. He admitted abusing large amounts of
14 nitrous oxide. Physical examination revealed absent ankle reflexes and an ataxic gait.
15 Superficial as well as deep sensory testing were affected. Romberg's sign was positive.

16 Laboratory testing revealed a normal vitamin B₁₂ (274 ng/L) but a clearly elevated HCy
17 (65.3 μmol/L), MMA (82 mmol/mol crea) and MCA (7 mmol/mol crea). MRI of the
18 cervical spine was normal and CSF testing showed no abnormalities, but EMG showed
19 an axonal-demyelinating polyneuropathy. Tibialis SEP was normal.

20 The differential diagnosis of polyneuropathy secondary to nitrous oxide abuse and acute
21 motor-sensory axonal neuropathy (AMSAN) was made. Because of a major functional
22 loss due to the symptoms, treatment was started without delay with both intravenous
23 immunoglobulin for five days and intramuscular cyanocobalamin before ~~the~~-all the
24 biochemical results were known, followed by in-hospital rehabilitation. He was lost to
25 follow-up.

1

2 **Case 8**

3 A 23-year-old male presented with subacute progressive numbness and paresthesia in
4 upper and lower limbs and gait problems. progressive since a couple of weeks. He
5 admitted abusing nitrous oxide. Physical examination revealed weak deep tendon reflexes
6 and absent ankle reflexes as well as an ataxic gait. Superficial as well as deep sensory
7 testing were affected. Romberg's sign was positive.

8 Laboratory workup showed a normal vitamin B₁₂ (247 ng/l) and an elevated HCy (54.5
9 μmol/L), MMA (43 mmol/mol crea) and MCA (3 mmol/mol crea). EMG revealed an
10 axonal sensorimotor polyneuropathy and MRI of the cervical spine showed an inverted
11 V-sign on the axial FS T2-WI. Tibialis SEP was abnormal.

12 He was treated with intramuscular cyanocobalamin and his gait improved gradually.

13

1 **Discussion**

2 Nitrous oxide was first used as an inhaled anesthetic in 1844. The first description of
3 nitrous oxide as a recreational drug dates already from the end of the nineteenth century
4 (8). The inhalation of nitrous oxide causes a euphoric feeling but lasts for only one
5 minute. It has gained popularity as a recreational drug in recent years and even more so
6 during corona ‘lockdown parties’. It is still legal in Belgium, although efforts are being
7 made to change legislation, especially for minors. The eight patients we present in this
8 case series were seen in our regional hospital in a 15-month period during the COVID-
9 19 pandemic. It is well known that nitrous oxide use can cause secondary functional
10 vitamin B₁₂ deficiency. Sometimes cyanocobalamin supplementation tablets are even
11 sold alongside nitrous oxide.

12 From the patient’s perspective the most important clinical neurological consequence that
13 persuades him or her to seek medical attention are gait problems. All our patients had a
14 subacute recent onset of complaints, ranging from a couple of days to weeks. Long term
15 neuropsychiatric symptoms, which often only present after long prolonged term vitamin
16 B12 deficiency, might not develop within present at this a couple of weeks interval.

17 Vitamin B₁₂ deficiency causes toxic myelopathy and is specifically pernicious to the
18 posterior columns of the spinal cord causing sensory ataxia. In cases one, two, four, five,
19 seven and eight the sensory ataxia was the most important clinical sign with a broad-
20 based gait and positive Romberg’s sign. All six of them admitted the recreational use of
21 nitrous oxide. However, the patient of case four used it only once, but mentioned the
22 frequent exposure to other people abusing it. We previously described the possible toxic
23 effect in innocent bystanders earlier-(6, 7).

24
25

1

2 ***Vitamin B₁₂ metabolism***

3 The two most important locations for the uptake of vitamin B₁₂ (cobalamin) are the
4 stomach and terminal ileum. Intrinsic factor, produced by the parietal cells in the stomach,
5 is essential for adequate absorption in the terminal ileum. One of the most common causes
6 of vitamin B₁₂ deficiency in older patients is autoimmune gastritis with a lack of intrinsic
7 factor (pernicious anemia). It can be detected by testing the serum of the patient for
8 parietal cell antibodies and intrinsic factor antibodies which are present in respectively
9 80% to 90% and 50% to 60% of patients with pernicious anemia (9). Another significant
10 cause of vitamin B₁₂ deficiency is a disease of the terminal ileum like Crohn disease.

11 Vitamin B₁₂ in plasma is bound to two types of proteins: holotranscobalamin (30%) and
12 holohaptocorrin (70%). Holotranscobalamin is the active form of cobalamin and is the
13 most important due to its essential role in the uptake of vitamin B₁₂ into the cells and
14 tissues. ~~The analysis of vitamin B₁₂ bound to transcobalamin, however, is not routinely~~
15 ~~performed in laboratories due to the higher cost~~ (10):

16 Cobalamin has two major forms that are used as co-factor in two metabolic pathways:
17 adenosyl cobalamin and methyl cobalamin. Adenosyl cobalamin plays a major role in
18 converting methylmalonyl-CoA to Succinyl-CoA, while methyl cobalamin assists in
19 converting homocysteine to methionine (11).

20 Nitrous oxide oxidates the cobalt ion in cobalamin and irreversibly inactivates the enzyme
21 methionine synthetase. This impairs the production of methionine from homocysteine
22 (12). Methionine is used in the synthesis of thymine, in turn an essential nucleobase for
23 DNA. In case of vitamin B₁₂ depletion there will be a problem in the DNA-synthesis
24 which will cause megaloblastic anemia. As another result of the lack of methionine,

1 myelin proteins can't be methylated and thus cause demyelination within the central and
2 peripheral nervous systems (11).

3 We can assume this is not the only pathophysiological mechanism of nitrous oxide
4 because not all patients develop subacute combined degeneration. Two cases were
5 described with sensorimotor peripheral neuropathy and a history of nitrous oxide abuse
6 without imaging evidence of myelopathy (11). This is also true for our patient of case
7 seven. It seems not every biochemical mechanism of nitrous oxide abuse is known to this
8 date (9).

9

10 **Biochemical analyses**

11 In all our cases, except for case three, normal cobalamin levels were measured. However,
12 this does not exclude a functional vitamin B₁₂ deficiency. Even when the serum level of
13 vitamin B₁₂ is normal, it is still possible that there is a functional depletion of vitamin B₁₂
14 in the body tissues. The analysis of active vitamin B₁₂ (holotranscobalamin) is considered
15 a more reliable sensitive test for vitamin B₁₂ deficiency, especially as an early marker.
16 (13). Holotranscobalamin was, however, normal in the 4 patients in whom this was tested
17 (see Table 1). Our laboratory recently started performing this analysis. Not unimportant,
18 there is also the recurring problem of variability in cut-off values depending on the
19 laboratory where this active vitamin B₁₂ is analyzed. If the result is in the indeterminate
20 'grey zone',
21 confirmatory testing is needed in order to determine its clinical relevance.

22 Therefore To rule out a possible vitamin B₁₂ deficiency, fasting HCy in plasma and MMA
23 and methylcitrate MCA in urine must be analyzed determined (14). Alternatively, MMA
24 can also be measured in plasma, which is more practical and less time-consuming, but
25 this test is not reimbursed in Belgium. The elevated fasting plasma HCy and the organic

Met opmerkingen [PV1]: Ik zou dit weglaten want dit geld toek voor gewoon B12.

1 ~~acids~~ increased MMA in urine ~~is~~ are the result of accumulation because they cannot be
2 converted into methionine or Succinyl-CoA, respectively, due to a functional depletion
3 of cobalamin. We noted that both HCy level in plasma and MMA ~~and methylcitrate~~ in
4 urine ~~was~~ere elevated in all patients, except for the second patient ~~where MMA and~~
5 ~~methylcitrate~~ in urine ~~were~~ was only measured after treatment was started.

Met opmerkingen [PV2]: MCA is formed when C3 is incorporated instead of C2 in the citric acid cycle in case of accumulation of propionyl-CoA (also in propionic academia upstream from methylmalonyl mutase).

Met opmerkingen [PV3]: Zou MCA weglaten voor eenvoud

6 Of note, a mild to moderate increase of HCy and MMA can also be caused by a reduced
7 renal function, as both are excreted in urine. In addition, HCy can also be -elevated in
8 case of depletion of folic acid or vitamin B₆ (10).

9 While vitamin B₁₂ depletion can cause megaloblastic anemia, patients with neurological
10 complications secondary to functional vitamin B₁₂ deficiency have a normal MCV in 25%
11 of the cases. A normal MCV therefore can't be used as an exclusion criterium (1).

12 Given the detrimental neurological complications of vitamin B₁₂ deficiency, the clinical
13 picture plays a crucial role in the diagnosis and the treatment should not be delayed in
14 case of doubtful biochemical findings (1).

16 **Imaging**

17 The clinical picture of our patients can largely be explained by spinal cord demyelination.
18 On MRI, ~~this the demyelination due to vitamin B12 deficiency~~ typically involves the
19 dorsal columns of the spinal cord bilaterally over a long segment extending over three or
20 more cervical segments usually extending from C2 to C6. ~~These MRI findings are specific~~
21 ~~to vitamin B₁₂ deficiency, not to a specific reason of this deficiency.~~ In other
22 demyelinating diseases, like multiple sclerosis, the hyperintense lesions are shorter and
23 transverse myelitis is differentiated by predominant localisation in the anterior and lateral
24 columns of the spinal cord with even longer involvement (15).

1 The lesion conspicuity can be increased by using dedicated sequences for demyelination.
2 In addition to routine sagittal T1- and T2 sequences (16) and T2* weighed spoiled
3 gradient echo sequence (GRE), we recommend using sagittal and axial images with fat
4 suppression. Axial images should be prescribed on the areas of abnormal signal seen on
5 the sagittal images. Involvement of the dorsal columns results in the inverted V-sign,
6 resembling inverted rabbit ears on axial images (17, 18).
7 Furthermore, in case of high clinical suspicion of demyelination, it is of utmost
8 importance to inform the radiologist appropriately, and specifically ask for demyelination
9 and/or fat suppression when planning cervical MRI imaging. Not using the best sequence,
10 with fat suppression, may result in failure to detect pathological signs. Figures 2B and C
11 show an axial T2* weighed spoiled gradient echo sequence and FS T2-WI respectively
12 on the same level and in the same patient. The lesion is clearly better visible on the FS
13 T2-WI.

14

15 *Electrophysiological testing*

16 Peripheral neuropathy on EMG and prolonged SEP's are common in vitamin B12
17 deficiency. This is especially true when there are neurological complaints, and might even
18 correlate with the disease severity and prognosis (19)([ref-puri-et-al-2005](#)). Even in
19 asymptomatic – or subclinical - patients with vitamin B12 deficiency, somatosensory
20 evoked potentials might be abnormal (20)([ref-Gökeç-Cokal-et-al-2016](#)).
21 In our patient group, The six out of eight patients who had an EMG; all of them were had
22 an abnormal result. In four of them EMG showed- mostly axonal damage was seen, in
23 four of the patients and in two out of the six, there was a mixed axonal-demyelinating
24 image damage in two patients. This seems to correspond results are in line with to previous

1 ~~studies by described populations (19, 20) (ref ref puri et al 2005 and ref Gökçe Cokal et~~
2 ~~at 2016).~~

3 ~~In five patients, somatosensory evoked potentials were performed. In all but one, tibialis~~
4 ~~SEP was abnormal. This also corresponds to previous reports (20).~~

5 ~~The electrophysiological test had no added value In for the clinical differential diagnosis~~
6 ~~in our patients however, these results did not really make a difference. It is possible that~~
7 ~~results of electrophysiological testing are is correlated with disease severity and prognosis~~
8 ~~(19) (ref Puri et al), but this was not the topic of our research.~~

12 **Treatment**

13 The treatment of choice in patients with vitamin B₁₂ deficiency caused by nitrous oxide
14 abuse is suppletion by intramuscular injections of cyanocobalamin of 1000 µg, besides
15 of course the cessation of nitrous oxide abuse. There is no clear-cut guideline available
16 in literature about frequency and duration of this treatment. In our hospital the following
17 scheme was used: one injection every day for one week, followed by one injection every
18 week for one month and finally one injection every month for five months. Thus, a total
19 treatment duration of six months.

20 Another common approach is intramuscular cyanocobalamin 1000 µg daily for a
21 minimum of five days followed by a four-week regimen of 1000 µg intramuscular weekly
22 (21). Oral administration of cyanocobalamin has proved to be as effective as
23 intramuscular injections at a dose of 1000 to 2000 µg daily for one to two weeks, followed
24 by maintenance of 1000 µg daily (21).

1 ~~A recent case report also suggested the combination of intramuscular vitamin B₁₂~~
2 ~~injections 500 µg per day for 19 days and intravenous Methylprednisolone 500 mg per~~
3 ~~day for five days, followed by oral vitamin B₁₂ 500 µg per day and methylprednisolone~~
4 ~~20 mg per day. No duration for oral treatment was mentioned in the study.~~
5 ~~Methylprednisolone was added because of the subacute combined degeneration due to~~
6 ~~demyelination in a patient with vitamin B₁₂ deficiency secondary to nitrous oxide abuse.~~
7 ~~Other possible causes of demyelination were excluded thanks to extensive analyses on~~
8 ~~serum and CSF. There was a complete recovery, clinical and radiological, in this patient~~
9 ~~in only eight months (22).~~

10 In literature a methionine supplementation has also [been](#) suggested as a possible treatment
11 option, but methionine is not standard available at hospital dispensaries and the
12 methionine supplementation will only correct the lack of methionine (21).

13 Although 86% of patients with myeloneuropathy treated with cyanocobalamin have some
14 recovery, only 14% fully recover 1 to 84 weeks after diagnosis. (12)

15 When there is suspicion of a hereditary cobalamin C/D deficiency, for example in patients
16 with a remarkably high level of MMA or ~~MCA~~[methylcitrate](#), or a confirmed MMACHC
17 gene mutation, treatment consists of intramuscular injections of hydroxocobalamin.

18 Because of the [relative](#) high levels of MMA and ~~methylcitrate~~[MCA](#) in case one, we
19 treated this patient with hydroxocobalamin in anticipation of the results of his genetic
20 testing for a MMACHC gene mutation. Afterwards this returned to be negative.

21 Intramuscular injections of cyanocobalamin in patients with a hereditary C/D deficiency
22 are not useful, because cyanocobalamin is an inactive form that must be activated and
23 converted by cobalamin reductase, an enzyme produced by the MMACHC gene. (23)

24
25 **Conclusion**

1 There is an increasing number of patients in clinical practice with neurological symptoms
2 due to vitamin B₁₂ deficiency in the setting of nitrous oxide abuse. Diagnosis is not always
3 straightforward. Clinical examination and patient interview, including possible nitrous
4 oxide exposure, is essential to avoid a missed diagnosis of nitrous oxide abuse. With
5 respect to biochemical testing, vitamin B₁₂ level alone is often not sensitive enough in the
6 setting of nitrous oxide use. Homocysteine level in serum and [urine organic acid analysis](#)
7 (MMA and [methylcitrate MCA](#)) ~~in urine~~ are useful, although not with perfect specificity.
8 The use of dedicated MR sequences, such as T2-WI in combination with fat-suppressed
9 techniques, is useful to increase lesion detection and precise evaluation of the extent of
10 the lesion. Treatment should be started as soon as possible. Prognosis is variable, but
11 correct and timely treatment are essential.

1 **Figure legend**

2 [Figure 1: inverted V-sign on axial FS T2-WI in the patient of case 3.](#)

3 [Figure 2: hyperintense signal of the dorsal columns extending from C2 to C6 on sagittal](#)

4 [T2-WI \(A\) and inverted V-sign on axial FS T2-WI \(C\) in the patient of case 4.](#)

5

6 [Figure 2 \(B and C\): axial T2* weighed spoiled gradient echo sequence \(B\) and FS T2-](#)

7 [WI \(C\) respectively on the same level in the patient of case 4.](#)

8 [Abbreviations: FS, fat suppression; WI, weighted image.](#)

Met opmaak: Lettertype: Niet Vet

1 **Table 1: clinical, biochemical, and radiological characteristics of our patients.**

Case	M/F	Symptoms			Biochemical results								MRI
		numbness and paresthesia	hypo- to areflexia	ataxic gait	vitamin B ₁₂ (187-883 ng/L)	Active vitamin B ₁₂ (20-134 pmol/L)	HCy (7.0-15.0 μmol/L)	MMA (<1 mmol/mol crea)	MCA (< or = 2 mmol/mol crea)	Hb (g/dL)	RBC (10*6/μL)	MCV (84-96 fL)	
1	M	T6 level and lower limbs	no	yes	220	NM	59.5	427	21	15.2	4.58	96	inverted V-sign
2	M	upper and lower limbs	yes	yes	482	NM	39.0	<10*	0 not detectable	16.8	5.49	86	doubtful inverted V-sign
3	M	upper and lower limbs	yes	no	180	NM	44.6	9	9	16.5	5.06	92	normal
4	F	upper and lower limbs	areflexia	yes	330	NM	25.9	31	5	13.9	5.24	87	normal
5	F	upper and lower limbs	yes	yes	280	36.4	32.4	10	1	13.7	4.12	97	normal
6	M	upper and lower limbs	no	no	280	23.7	48.5	4	3	15.3	5.04	93	normal
7	M	upper and lower limbs	yes	yes	274	65.5	65.3	82	7	13.7	4.09	98	normal
8	M	upper and lower limbs	yes	yes	247	32.2	54.5	43	3	16.3	4.99	92	normal

2 * results after start of treatment

3 Abbreviations: M, male; F, female; NM, not measured; HCy, homocysteine; MMA, methylmalonic acid; MCA, 2-methylcitric acid; Hb, hemoglobin; RBC, red blood cell count; MCV, mean corpuscular volume; MRI, magnetic resonance imaging.

5 Reference values: Vitamin B₁₂: 187-883 ng/L; HCy: 7.0-15.0 μmol/L; MMA: ≤1 mmol/mol; MCA: < or = 2 mmol/mol; MCV: 84-96 fL

← In Tabel met opmaak

Met opmaak: Lettertype: 11 pt

Met opmaak: Lettertype: 11 pt

Met opmaak: Lettertype: 11 pt

Met opmaak: Lettertype: 11 pt

Met opmaak: Centrum

Met opmaak: Lettertype: 11 pt

Met opmaak: Lettertype: 11 pt

Met opmaak: Links

Met opmaak: Lettertype: 11 pt

Met opmaak: Lettertype: 11 pt

Met opmaak: Subscript

- 1 [Methods: Vitamin B12 and holotranscobalamin were determined with Alinity \(Abbott\), Hcy with ACL Top 500 \(Werfen\), and MMA and MCA with gas chromatography mass spectrometry.](#)
- 2

References

1. Devalia V, Hamilton MS, Molloy AM. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. *British journal of haematology*. 2014;166(4):496-513.
2. Carmel R. Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II. *The American journal of clinical nutrition*. 2011;94(1):348s-58s.
3. Lynch KL. Commentary. *Clinical Chemistry*. 2017;63(6):1072-3.
4. Conjaerts SHP, Bruijnes JE, Beerhorst K, Beekman R. [Nitrous oxide-induced polyneuropathy]. *Nederlands tijdschrift voor geneeskunde*. 2017;161:D2044.
5. Garakani A, Jaffe RJ, Savla D, Welch AK, Protin CA, Bryson EO, et al. Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case literature. *The American journal on addictions*. 2016;25(5):358-69.
6. Sluyts Y, Pals P, Amir R, Vanherpe P. Recreational use of nitrous oxide may cause collateral neurological damage. *Acta neurologica Belgica*. 2021;121(4):1097-9.
7. Sluyts Y, Pals P, Amir R, Vanherpe P. Recreational use of nitrous oxide may cause collateral neurological damage. *Acta neurologica Belgica*. 2021.
8. Blanco G, Peters HA. Myeloneuropathy and macrocytosis associated with nitrous oxide abuse. *Archives of neurology*. 1983;40(7):416-8.
9. Duque MA, Kresak JL, Falchook A, Harris NS. Nitrous Oxide Abuse and Vitamin B12 Action in a 20-Year-Old Woman: A Case Report. *Laboratory medicine*. 2015;46(4):312-5.
10. Tjerk Wiersma HW-K. NHG-Standpunt Diagnostiek van vitamine-B12-deficiëntie. *Huisarts & Wetenschap* 2014;57(9):472-5.
11. Thompson AG, Leite MI, Lunn MP, Bennett DL. Whippits, nitrous oxide and the dangers of legal highs. *Practical neurology*. 2015;15(3):207-9.
12. Edigin E, Ajiboye O, Nathani A. Nitrous Oxide-induced B12 Deficiency Presenting With Myeloneuropathy. *Cureus*. 2019;11(8):e5331.
13. Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. *BMJ (Clinical research ed)*. 2014;349:g5226.
14. Green R, Allen LH, Bjørke-Monsen AL, Brito A, Guéant JL, Miller JW, et al. Vitamin B(12) deficiency. *Nature reviews Disease primers*. 2017;3:17040.
15. Granados Sanchez AM, Garcia Posada, Lina Maria, Ortega Toscano, Cesar Andres, & Lopez Lopez, Alejandra Diagnostic Approach to Myelopathies. . *Revista Colombiana de Radiologia*. 2011;22(3):3231-51.
16. Asiri A, Dimpudus F, Atcheson N, Al-Najjar A, McMahon K, Kurniawan ND. Comparison between 2D and 3D MEDIC for human cervical spinal cord MRI at 3T. *Journal of medical radiation sciences*. 2021;68(1):4-12.
17. Vael L, Phyllis VW, Özsarlak Ö. MRI of Nitrous Oxide-Related Subacute Cervical Myelopathy. *Journal of the Belgian Society of Radiology*. 2021;105(1):22.
18. Yuan JL, Wang SK, Jiang T, Hu WL. Nitrous oxide induced subacute combined degeneration with longitudinally extensive myelopathy with inverted V-sign on spinal MRI: a case report and literature review. *BMC neurology*. 2017;17(1):222.
19. Puri V, Chaudhry N, Goel S, Gulati P, Nehru R, Chowdhury D. Vitamin B12 deficiency: a clinical and electrophysiological profile. *Electromyography and clinical neurophysiology*. 2005;45(5):273-84.
20. Gökçe Çokal B, Güneş HN, Güler SK, Yoldaş TK. Visual and somatosensory evoked potentials in asymptomatic patients with vitamin B12 deficiency. *European review for medical and pharmacological sciences*. 2016;20(21):4525-9.
21. Pugliese RS, Slagle EJ, Oettinger GR, Neuburger KJ, Ambrose TM. Subacute combined degeneration of the spinal cord in a patient abusing nitrous oxide and self-medicating with

1 cyanocobalamin. American journal of health-system pharmacy : AJHP : official journal of the
2 American Society of Health-System Pharmacists. 2015;72(11):952-7.

3 22. Zhang S, Zhou Z, Wu W, Yu Q, Hong M. Methylprednisolone combined vitamin
4 supplementation reversed rapidly subacute combined degeneration of the spinal cord induced
5 by the abuse of nitrous oxide. Acta neurologica Belgica. 2021.

6 23. Huemer M, Diodato D, Schwahn B, Schiff M, Bandeira A, Benoist JF, et al. Guidelines for
7 diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE,
8 cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40(1):21-48.

9